Publication
EAACI guidelines on the management of IgE-mediated food allergy.
Journal Paper/Review - Oct 30, 2024
Santos Alexandra, Riggioni Carmen, Agache Ioana Octavia, Akdis Cezmi A, Akdis Mübeccel, Alvarez-Perea Alberto, Alvaro-Lozano Montserrat, Ballmer-Weber Barbara, Barni Simona, Beyer Kirsten, Bindslev-Jensen Carsten, Brough Helen Annaruth, Buyuktiryaki Betul, Chu Derek, Del Giacco Stefano, Dunn Galvin Audrey, Eberlein Bernadette, Ebisawa Motohiro, Eigenmann Philippe, Eiwegger Thomas, Feeney Mary, Fernández-Rivas Montserrat, Fiocchi Alessandro, Fisher Helen R, Fleischer David M, Giovannini Mattia, Gray Claudia, Hoffmann-Sommergruber Karin, Halken Susanne, Hourihane Jonathan O'B, Jones Christina J, Jutel Marek, Knol Edward, Konstantinou George N, Lack Gideon, Lau Susanne, Marques Mejias Andreina, Marchisotto Mary Jane, Meyer Rosan, Mortz Charlotte G, Moya Beatriz, Muraro Antonella, Nilsson Caroline, Lopes de Oliveira Lucila Camargo, O'Mahony Liam, Papadopoulos Nikolaos G, Perrett Kirsten, Peters Rachel L, Podestà Marcia, Poulsen Lars K, Roberts Graham, Sampson Hugh A, Schwarze Jürgen, Smith Peter Kenneth, Tham Elizabeth Huiwen, Untersmayr Eva, Van Ree Ronald, Venter Carina, Vickery Brian P, Vlieg-Boerstra Berber, Werfel Thomas, Worm Margitta, du Toit George, Skypala Isabel
Units
PubMed
Doi
Contact
Citation
Type
Journal
Publication Date
Issn Electronic
Brief description/objective
This European Academy of Allergy and Clinical Immunology (EAACI) guideline provides recommendations for the management of IgE-mediated food allergy and was developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Following the confirmation of IgE-mediated food allergy diagnosis, allergen avoidance and dietary advice (with support of a specialised dietitian, if possible) together with the provision of a written treatment plan, education on the recognition of allergic symptoms and prescription of medication including adrenaline using an auto-injector are essential. Patients with significant anxiety and requirement for coping strategies may benefit from support from a clinical psychologist. As immunomodulatory interventions, omalizumab is suggested for treatment of IgE-mediated food allergy in children from the age of 1 and adults; and oral allergen-specific immunotherapy is recommended for children and adolescents with peanut allergy and suggested for milk and egg allergies (generally after 4 years of age for milk and egg). Sublingual and epicutaneous immunotherapy are suggested for peanut allergy but are not yet available at the point of care. Future research into disease modifying treatments for IgE-mediated food allergy are highly needed, with standardised and patient-focused protocols and outcomes.